TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02446847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: 3BNC117 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: 3BNC117 infusions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART Interruption
Description: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART Interruption
Description: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
Study: NCT04074330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.
Study: NCT02579395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual implementation Intentions
Description: Without spouse/romantic partner

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Study: NCT02265809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Study: NCT04232267

Intervention type: DEVICE
Intervention: MEB-001
Description: Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
Study: NCT03000790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual Ring Splint
Description: A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue
Study: NCT00441922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study: NCT02579772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
Study: NCT04652661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 30 children will be sedated with 2 μg/kg intranasal DEX.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 30 children will be sedated with 0.3 mg/kg intranasal midazolam.
Study: NCT04074330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.
Study: NCT04788342

Intervention type: DEVICE
Intervention: pulse wave recording, echocardiography.
Description: pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
Study: NCT02643147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Strategy
Description: The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
Study: NCT03007797

Intervention type: BEHAVIORAL
Intervention: vaccination rate for influenza
Study: NCT03169998

Intervention type: DEVICE
Intervention: EV1000 platform
Description: a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
Study: NCT04001335

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental Broach
Description: Dental broach, RDT and PCR
Study: NCT00486252

Intervention type: OTHER
Intervention: Observational
Description: This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
Study: NCT04074330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.
Study: NCT02645123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Enraf-Nonius Sonopuls 692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal mobilization
Description: passive physiological intervertebral movements and passive accessory posteroanterior mobilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: swedish type massage
Description: petrissage, effleurage, tapotement
Study: NCT04074330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.
Study: NCT02829385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and XELOX combined treatment group
Description: Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.
Study: NCT04626661

Intervention type: DEVICE
Intervention: COMET measurement system
Description: Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.

Intervention type: DEVICE
Intervention: COMET measurement system
Description: Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
Study: NCT02188524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Tai Chi and Compensatory Stepping
Study: NCT02645123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static hamstring stretch
Description: static hamstring stretching

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: touching of the skin overlying the lumbar area
Study: NCT02314351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10 mg
Description: Intravenous form of metoclopramide is in the same appearance with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide 10 mg
Description: Intravenous form of metoclopramide is in the same appearance with placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous form of metoclopramide is in the same appearance with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous form of metoclopramide is in the same appearance with placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Study: NCT00203034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: 0.5 mg rasagiline mesylate oral once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg rasagiline mesylate
Description: 1.0 mg rasagiline mesylate oral once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily
Study: NCT02559310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lefamulin
Description: antibacterial agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: antibacterial agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: antibacterial agent
Study: NCT01376154

Intervention type: DRUG
Intervention: Lamivudine
Study: NCT04463680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 MG
Description: Administered daily for 2 weeks
Study: NCT02536742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Study: NCT03298269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
Study: NCT03753243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
Study: NCT02605369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: An integrated package
Description: See description in previous column
Study: NCT00938405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Description: 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
Study: NCT01317329

Intervention type: OTHER
Group type: OTHER
Intervention: Clinically prescribed CPAP therapy
Description: CPAP as prescribed by attending physician
Study: NCT00134355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Study: NCT04187859

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education Session
Description: Participants will receive an education session from their District Nurse, advising on how to improve their hydration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education Session
Description: Participants will receive an education session from their District Nurse, advising on how to improve their hydration.

Intervention type: DEVICE
Group type: OTHER
Intervention: Prompting Cup
Description: The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink

Intervention type: DEVICE
Group type: OTHER
Intervention: Prompting Cup
Description: The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
Study: NCT03277352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat will be self-administered orally at the protocol-defined dose.
Study: NCT03125850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomized to day ward
Description: Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: randomized to inpaitent
Description: Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
Study: NCT00042653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
Study: NCT00076999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV oral solution
Description: Tipranavir oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV oral solution
Description: Tipranavir oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV oral solution
Description: Ritonavir oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV oral solution
Description: Ritonavir oral solution
Study: NCT02708797

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial Doppler
Description: Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial Doppler
Description: Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
Study: NCT02415231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: humor
Study: NCT03438864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy, interferential current
Description: Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy, interferential current
Description: Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No current except for first 5 seconds, device open but does not appy electrotherapy.
Study: NCT04949204

Intervention type: PROCEDURE
Intervention: Wearable sensor detection
Description: Empatica E4 wearable wrist sensor

Intervention type: PROCEDURE
Intervention: Wearable sensor detection
Description: Empatica E4 wearable wrist sensor
Study: NCT05861206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)
Description: Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHX-MW group (0.12% CHX, as a positive control group)
Description: Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
Study: NCT03277352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV at the protocol-defined dose.
Study: NCT00707499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: Single dose administration.
Study: NCT02284009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide weekly injection
Description: Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo weekly injection
Description: Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
Study: NCT02923505

Intervention type: PROCEDURE
Intervention: polygraphy or polysomnography

Intervention type: PROCEDURE
Intervention: polygraphy or polysomnography

Intervention type: PROCEDURE
Intervention: polygraphy or polysomnography
Study: NCT03652350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided microwave ablation
Description: Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
Study: NCT01729715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD